Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ004309 + toripalimab vs toripalimab vs pembrolizumab in untreated advanced PD-L1/CD73-selected non-small cell lung cancer
CTR20240650Phase 3Active
- Sponsor
- I-Mab
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of uliledlimab, toripalimab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by I-Mab. Started Apr 2024; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240650.